- Home
- REVBW vs MRK Comparison
REVBW vs MRK Comparison
Compare REVBW & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVBW
- MRK
- Stock Information
- Founded
- REVBW N/A
- MRK 2000
- Country
- REVBW United States
- MRK United States
- Employees
- REVBW 9
- MRK N/A
- Industry
- REVBW Biotechnology: Pharmaceutical Preparations
- MRK Biotechnology: Pharmaceutical Preparations
- Sector
- REVBW Health Care
- MRK Health Care
- Exchange
- REVBW Nasdaq
- MRK Nasdaq
- Market Cap
- REVBW N/A
- MRK N/A
- IPO Year
- REVBW 2020
- MRK N/A
- Fundamental
- Price
- REVBW $0.02
- MRK $89.50
- Analyst Decision
- REVBW
- MRK Buy
- Analyst Count
- REVBW 0
- MRK 17
- Target Price
- REVBW N/A
- MRK $120.31
- AVG Volume (30 Days)
- REVBW N/A
- MRK 18.6M
- Earning Date
- REVBW N/A
- MRK 02-04-2025
- Dividend Yield
- REVBW N/A
- MRK 3.62%
- EPS Growth
- REVBW N/A
- MRK 4711.66
- EPS
- REVBW N/A
- MRK 6.74
- Revenue
- REVBW N/A
- MRK $64,168,000,000.00
- Revenue This Year
- REVBW N/A
- MRK $2.57
- Revenue Next Year
- REVBW N/A
- MRK $6.21
- P/E Ratio
- REVBW N/A
- MRK $13.29
- Revenue Growth
- REVBW N/A
- MRK 6.74
- 52 Week Low
- REVBW N/A
- MRK $81.04
- 52 Week High
- REVBW N/A
- MRK $134.63
- Technical
- Relative Strength Index (RSI)
- REVBW N/A
- MRK 45.20
- Support Level
- REVBW N/A
- MRK $81.04
- Resistance Level
- REVBW N/A
- MRK $100.15
- Average True Range (ATR)
- REVBW 0.00
- MRK 2.12
- MACD
- REVBW 0.00
- MRK 0.09
- Stochastic Oscillator
- REVBW 0.00
- MRK 44.27
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).